Sermorelin Acetate research guide
Acetate salt of amidated 29-residue GHRH fragment
What the Sermorelin Acetate name specifies, how GHRH(1-29)-amide differs from related analogues, and what a historical clinical study can and cannot establish.
AUS Peptide Supply editorial team01 · Identity
What the name identifies
Sermorelin is the amidated 29-residue amino-terminal fragment of human growth-hormone-releasing hormone. Sermorelin Acetate names its acetate salt form. The peptide sequence, salt designation and quantitative reporting basis should be recorded separately rather than compressed into a generic GHRH label.
02 · Evidence position
What the literature can support
The selected human study was a historical multicentre open-label investigation in children with growth-hormone deficiency. It is relevant to that studied product and population, not evidence of general anti-ageing or body-composition effects. Its design does not supply a modern batch identity or purity certificate.
03 · Study-level map
Evidence and its limits
What do the peptide and acetate names specify?
The PubChem reference identifies the amidated GHRH(1-29) peptide. The catalogue label separately specifies an acetate material designation.
Limit: A reference identity does not settle the counter-ion content, moisture or quantitative assay basis of a supplied sample.
What population and design appear in the historical trial?
The 1996 Geref study enrolled 110 previously untreated prepubertal children with growth-hormone deficiency in a multicentre open-label study lasting up to one year. Eighty-six were included in the efficacy analysis.
Limit: It was not a placebo-controlled demonstration of broad benefits in healthy adults. The study product does not verify this catalogue material.
04 · Analytical context
Questions a batch record should answer
- 01Do sequence and terminal amidation match the sermorelin reference identity?
- 02Is the acetate form and its reporting basis stated rather than assumed from a name?
- 03Does the measured amount refer to peptide content, total material or another explicitly defined quantity?
05 · Boundary conditions
What this record does not establish
- A common GHRH-related pathway does not make Sermorelin, CJC-1295 and Tesamorelin identical.
- No peptide-only mass is inferred from an unqualified vial quantity label.
- No verified APS CoA is available for the associated product at publication.
Sources checked
- 1.Sermorelin — PubChem CID 16132413
NIH PubChem · 2026 · Chemical database
- 2.Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.
Thorner et al. — Journal of Clinical Endocrinology & Metabolism / PubMed · 1996 · Primary study